The recent evolution of drug therapy for hypertension has primarily focused on new agents but there has been a renewed interest in the use of low doses of diuretic in
Introduction
Major changes have occurred in the recommendations for the initial treatment of hypertension. In the US, the recommendations from the 1988 Joint National Committee report (JNC-IV) were to use any of four classes of drugs: diuretics, beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs), or calcium antagonists (CAs). 1 In the 1993 JNC-V report, only diuretics or beta-blockers were recommended since these were the only drugs that had been tested in large-scale randomised controlled trials (RCTs) and thereby shown to reduce cardiovascular morbidity and mortality. 2 Despite the appropriate reasoning behind this more restricted recommendation, certainly in keeping with the rising demand for 'evidence-based medicine', opposition come from multiple sources that effectively countered the JNC-V position. 3 Despite this restricted recommendation, over the years from 1990 to 1996, the overall use of diuretics and beta-blockers fell, while the sales of ACEIs and CAs progressively rose 4 ( Figure 1 ). The opposition directed against the JNC-V recommendations came from some academicians 5 but more forcibly from major market forces, 6 extolling the multiple putative advantages of newer agents while harnessing the natural temptation of practitioners to forego the old in favour of the new, thereby keeping on the cutting edge of medical practice.
Meanwhile, multiple controlled clinical trials with the newer agents began to appear that documented their special attributes in a variety of specific situations. As a result, the 1997 sixth JNC report (JNC-VI) offered three pathways for initial therapy: (1) for uncomplicated hypertension; (2) for four 'compelling' indications; and (3) for a variety of spe- cific coexisting conditions where certain drugs had favourable influences 7 ( Figure 2 ). The rationale for the first two paths is firmly based on the evidence from randomised controlled trials (RCTs), while the third is more loosely based upon clinical experience without the backing of RCTs.
The 1999 World Health Organization -International Society of Hypertension guidelines 8 state that: 'All available drug classes are suitable for the initiation and maintenance of antihypertensive therapy' but then provide a number of factors that influence the choice, leading to a similar list of compelling indications for specific drugs as provided in the JNC-VI report.
The advent of low-dose combination therapy
Combinations of two or more antihypertensive drugs have been available for well over 30 years. However, the rather large doses of the individual components often caused adverse effects and an academically purist attitude favoured the use of individual drugs whose dose could separately be altered.
In the mid-1990s, an appreciation arose of the ability of truly low doses of two drugs to increase overall therapeutic efficacy, while keeping dosedependent side effects to a minimum. The following three drugs are now approved for initial therapy in Europe or the US: one with low dose of the ACEI perindopril (2 mg) and very low dose of the nonthiazide diuretic indapamide (0.625 mg); 9 two others with low dose of an ACEI (benazepril) or a low dose of a beta-blocker, bisoprolol, both with low doses of the diuretic hydrochlorothiazide (6.25 mg). 10, 11 As stated in the JNC-VI: 'Newly developed formulations provide additional medication choices. For example, combinations of low doses of two agents from different classes have been shown to provide additional antihypertensive efficacy, thereby minimising the likelihood of dosedependent adverse effects'. 7 As seen in Figure 2 , JNC-VI indicates the appropriateness of low dose combinations for initial therapy.
The 1999 WHO-ISH guidelines provide a similar affirmation of the value of combination therapy: 'Effective drug combinations utilize drugs from different classes in order to obtain the additive hypotensive effect that comes from combining drugs with different primary actions, while minimising the compensations that limit the fall in blood pressure'. 8 These guidelines also recommend low dose combinations to initiate therapy, stating that 'the use of the fixed low-dose combinations that are increasingly available in the United States and Europe may be advantageous'.
The importance of a diuretic component
A rapidly expanding group of low-dose combination formulations are being marketed. Although some of the combinations that do not include a diuretic may be appropriate for second-line therapy, 12 only combinations with a low dose of diuretic are currently approved in the US for initial therapy. This position will most likely hold.
Again, JNC-VI provides the rationale, stating that: 'If a diuretic is not chosen as the first drug, it usually indicated as a second-step agent because its addition will enhance the effects of other agents'. 7 This ability of sub-maximal doses of diuretic to enhance efficacy has been demonstrated with all other classes of drugs. 4 Moreover, the tendency for increased retention of sodium by the hypertensive kidney as non-diuretic drugs cause the blood pressure to fall has long been recognised as a cause of loss of antihypertensive efficacy that can immediately be restored by addition of a diuretic. 13 Therefore, there will likely be a continued growth of combinations of low-dose diuretic along with low-doses of all the other classes of antihypertensive drugs.
The non-thiazide diuretic indapamide fulfills the overall criteria for a diuretic to be used in combination with other antihypertensive agents since it effectively lowers the blood pressure and does not compromise serum cholesterol 14 or plasma glucose levels 15 while it also reduces left ventricular hypertrophy (LVH). 16 The formulation of perindopril and idapamide has been shown to provide multiple ancillary benefits in an experimental model of salt-sensitive hypertension. 17 Hopefully, the use of such low-dose combinations will provide effective reductions of blood pressure with minimal adverse effects, thereby improving patient adherence to long-term therapy and providing additional protection against premature cardiovascular disease.
Other combinations
Both the 1997 JNC-VI and the 1999 WHO-ISH guidelines provide a number of other rational combinations of drugs from different classes that do not include a low-dose diuretic. Although such combinations may provide good blood pressure control and ancillary benefits, they seem less suitable for initial therapy than those that include a low dose of diuretic. However, the increasing recognition that at least two drugs and often three or more are needed to achieve the degree of antihypertensive effect that is needed to protect high risk patients such as hypertensive diabetics, 18, 19 will provide additional momentum to the use of various combination therapies. 
